ææš
ææš
æ°å€
æ¹åæ§
MACD(12,26,9)
0.020
äžç«
RSI(14)
35.190
äžç«
STOCH(KDJ)(9,3,3)
23.650
äžç«
ATR(14)
0.132
é«å€åç
CCI(14)
-80.942
äžç«
Williams %R
85.088
売ããéã
TRIX(12,20)
-0.901
売ã
StochRSI(14)
42.742
売ã
îæ€çŽ¢
îæ€çŽ¢
î
Nervgen Pharma Ord Shs
NGENîãŠã©ãããªã¹ãã«è¿œå
1.670USD
-0.050-2.91%
çµå€Â 07-23 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
133.01Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
詳现ãã£ãŒãã衚瀺
TradingKeyãã£ãŒãIntraday
1m
30m
1h
D
W
M
D
æ¬æ¥
-2.91%
5æ¥é
0.00%
1ã¶æ
-18.93%
6ã¶æ
-67.06%
幎åæ¥
0.00%
1幎é
0.00%
äž»èŠããŒã¿
1.710å§å€
1.730é«å€
467.05Kåºæ¥é«
æ倱é¡çŽè¿12ã¶æPER
æ倱é¡äºæ³PER
--çŽè¿12ã¶æé
åœ
0.59%売買å転ç
1.720åæ¥çµå€
1.660å®å€
527.03K売買代é
--æ ªäŸ¡åçç
53.23PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-228.63%ç·è³ç£å©çç
6.30052é±é«å€
0.58åºæ¥é«æ¯ç%
--çŽå©ç
79.65Mæ ªåŒæ°
-0.41331æ ªåœããå©çïŒEPSïŒ
0.74ããŒã¿å€
-1207.46%èªå·±è³æ¬å©çç
1.50052é±å®å€
4.07%æ¯ãå¹
--ç²å©çç
133.01Mæ䟡ç·é¡
-3.26ãªã¹ã¯ãªã¿ãŒã³
4.16%ãªã¹ã¯ç
TradingKeyã®Nervgen Pharma Ord Shsã®æ ªåŒã¹ã³ã¢î
é貚: USD æŽæ°æå»: 2026-07-23äž»èŠã€ã³ãµã€ã
Nervgen Pharma Ord Shsã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçå¥å šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããã€ãªãã¯ãããžãŒ & å»çç 究æ¥çã§ã®é äœã¯386äž191äœã§ããæ©é¢æè³å®¶ä¿æçã¯æ¯èŒçé«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯10.21ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžéãã¬ã³ããšäºæ³ãããŸããæ ªåŒåžå Žã§ã®ããã©ãŒãã³ã¹ã¯ãã®1ãæã§äœèª¿ã§ããããå瀟ã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯å 調ã§ããæ ªäŸ¡ã¯æ¯æç·ãšæµæç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Nervgen Pharma Ord Shsã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ã¬ãŒããŒãã£ãŒã
çŸåš
ååå€
ã¡ãã£ã¢å ±é
éå»24æé
å ±éã¬ãã«
éåžžã«äœã
éåžžã«é«ã
äžç«
Nervgen Pharma Ord Shsã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
æé·äž
å瀟ã¯æé·ãã§ãŒãºã«ãããææ°ã®å¹Žéåçã¯USD 239.63Kã«éããŠããŸãã
ç¡é
å瀟ã¯éå»5幎éé
åœãæ¯æã£ãŠããŸããã
å²é«
å瀟ã®ææ°ã®PEã¯-4.05ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠé«å€åã«ãããŸãã
æ©é¢æè³å®¶ã®è²·ãå¢ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯350.93Kæ ªã§ãåååææ¯ã§46.35%å¢å ããŠããŸãã
ã¢ããªã¹ãè©äŸ¡
9
人ã®ã¢ããªã¹ãäºæ³ã«åºã¥ã
è²·ã
çŸåšã®è©äŸ¡
10.213
ç®æšæ ªäŸ¡
+473.74%
äžæäœå°
Nervgen Pharma Ord Shs ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
ã¢ããªã¹ãè©äŸ¡
9
人ã®ã¢ããªã¹ãäºæ³ã«åºã¥ã
è²·ã
çŸåšã®è©äŸ¡
10.213
ç®æšæ ªäŸ¡
+473.74%
äžæäœå°
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
åæ¥ä»ç€Ÿæ¯èŒ
495
åèš
6
äžå€®å€
7
å¹³å
äŒç€Ÿå
è©äŸ¡
ã¢ããªã¹ã
Nervgen Pharma Ord Shs
NGEN
9
Beigene Ltd
ONC
28
argenx SE
ARGX
27
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
ææšî
移åå¹³å
ææš
æ°å€
æ¹åæ§
MA5
1.715
売ã
MA10
1.749
売ã
MA20
1.866
売ã
MA50
2.207
売ã
MA100
3.083
売ã
MA200
3.454
売ã
財åææšî
EPS
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Nervgen Pharma Ord Shsã®äŒæ¥æ å ±î
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
äŒæ¥ã³ãŒãNGEN
äŒæ¥åNervgen Pharma Ord Shs
æé«çµå¶è²¬ä»»è
ãCEOãRogers (Adam H)
ãŠã§ããµã€ãhttps://www.nervgen.com/
æ ªäž»çµ±èšî
é¢é£éèåå
+1.95%
+1.46%
-0.85%
+1.43%
+2.37%
+2.01%
+1.49%
+0.38%
0.00%
+0.71%
+1.27%
+0.15%
-0.94%
-0.03%
+1.31%
0.00%
+0.11%
+8.61%
-0.21%
+2.45%人æ°éæ
51909.200
+185.200Â (+0.36%)
28466.900
-111.100Â (-0.39%)
7423.600
+3.700Â (+0.05%)
14999.000
-102.000Â (-0.68%)
64925.000
-446.000Â (-0.68%)
6243.300
+27.600Â (+0.44%)
89.523
-2.589Â (-2.81%)
321.680
-4.210Â (-1.29%)
208.770
-3.290Â (-1.55%)
4054.350
+4.980Â (+0.12%)
ãããã質å
Nervgen Pharma Ord ShsïŒNGENïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îNervgen Pharma Ord ShsïŒNGENïŒã®çŸåšã®æ ªäŸ¡ã¯1.67ã§ãã
Nervgen Pharma Ord Shsã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îNervgen Pharma Ord Shsã®ãã£ãã«ãŒã·ã³ãã«ã¯NGENã§ãã
Nervgen Pharma Ord Shsã®52é±é«å€ã¯ãããã§ããïŒ
îNervgen Pharma Ord Shsã®52é±é«å€ã¯6.30ã§ãã
Nervgen Pharma Ord Shsã®52é±å®å€ã¯ãããã§ããïŒ
îNervgen Pharma Ord Shsã®52é±å®å€ã¯1.50ã§ãã
Nervgen Pharma Ord Shsã®æ䟡ç·é¡ã¯ãããã§ããïŒ
îNervgen Pharma Ord Shsã®æ䟡ç·é¡ã¯133.01Mã§ãã
Nervgen Pharma Ord Shs (NGEN) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãNervgen Pharma Ord ShsïŒNGENïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯10.21ã§ãã
Nervgen Pharma Ord Shs (NGEN) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îNervgen Pharma Ord ShsïŒNGENïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-0.44ã§ãã